| abstract |
The invention relates to a pharmaceutical combination comprising a specific thienopyridone derivative, namely 2-chloro-4-hydroxy-3-(5-hydroxytetralin-6-yl)-5-phenyl-7H-thieno[2,3-b]pyridin-6-one or one of its pharmaceutically acceptable salts and/or solvates, and at least one farnesoid-X receptor (FXR) agonist. This combination may be used for treating a liver disease such as NASH, including cirrhotic and non-cirrhotic NASH. |